PHS
INMB icon

Pekin Hardy Strauss’s INmune Bio INMB Stock Holding History

Pekin Hardy Strauss’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-94,300
Closed -$736K – 384
2025
Q1 		$736K Buy
94,300
+10,950
+13% +$87K 0.09% 195
2024
Q4 		$389K Buy
+83,350
New +$435K 0.05% 272

Other funds holding INMB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Pekin Hardy Strauss's INMB Position: Q2 2025 in Review

Pekin Hardy Strauss sold out of INmune Bio (INMB) in Q2 2025, closing a stake of 94,300 shares — an estimated $736K sold.

Pekin Hardy Strauss first reported a position in INMB in Q4 2024 and held it in 2 quarters. The position peaked at $736K in Q1 2025. 79 funds tracked by Wall St. Rank hold INMB as of Q2 2025.

  • Pekin Hardy Strauss reported no remaining INmune Bio position as of Q2 2025 after selling out during the quarter.
  • Pekin Hardy Strauss sold 94,300 INmune Bio shares in Q2 2025, an estimated $736K.
  • Pekin Hardy Strauss first reported a position in INmune Bio in Q4 2024 and held it in 2 quarters.
  • Pekin Hardy Strauss's INmune Bio position peaked at $736K in Q1 2025.
  • 79 funds tracked by Wall St. Rank held INmune Bio as of Q2 2025.

Based on Pekin Hardy Strauss's 13F filing for Q2 2025, filed 6 Aug 2025.